In the BioHarmony Drug Report Database

"Preview" Icon

Ketoconazole

Extina, Nizoral, Nizoral Anti-dandruff, Xolegel, Ketoconazole HRA (ketoconazole) is a small molecule pharmaceutical. Ketoconazole was first approved as Extina on 1982-01-01. It is used to treat acanthamoeba keratitis, blastomycosis, chronic mucocutaneous candidiasis, coccidioidomycosis, and cutaneous candidiasis amongst others in the USA. It has been approved in Europe to treat cushing syndrome. It is known to target potassium voltage-gated channel subfamily A member 10 and lanosterol 14-alpha demethylase.

 

Trade Name

 

Ketoconazole HRA
 

Common Name

 

ketoconazole
 

ChEMBL ID

 

CHEMBL157101
 

Indication

 

acanthamoeba keratitis, blastomycosis, chronic mucocutaneous candidiasis, coccidioidomycosis, cushing syndrome, cutaneous candidiasis, histoplasmosis, leishmaniasis, mycoses, oral candidiasis, paracoccidioidomycosis, seborrheic dermatitis, tinea pedis, tinea versicolor, vulvovaginal candidiasis
 

Drug Class

 

Systemic antifungals (miconazole type)

Image (chem structure or protein)

Ketoconazole structure rendering